Jarushka Naidoo, Full Professor of Medical Oncology at the Royal College of Surgeons in Ireland, shared a post on X about a recent paper by Zhiwei Chen et al. published in the Journal of Thoracic Oncology:

“Phase Ib Trial Ivonescimab (PD-1/VEGF bispecific)+Plt/Etop in 1L ES SCLC in Journal of Thoracic Oncology:

Ivo (3 dose levels)+plt/etopx4 – ivo maintenance
35pts, ORR 80%, DCR 91%
g3+ TRAEs 60% (low ANC, WBC, Hb)

Intriguing. VEGF is not a traditional SCLC target.”

“Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial”

Authors: Zhiwei Chen, Lin Wu, Qiming Wang, Xiao Xu, Shun Lu et al.

Jarushka Naidoo: Phase Ib Trial on Ivonescimab with Etoposide Plus Carboplatin in 1st line ES SCLC

More posts featuring Jarushka Naidoo.